Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of solid tumor

- Advanced or metastatic disease* NOTE: *With the exception of colorectal and lung
cancer patients, all patients must receive approval from the insurance carrier
that allows for coverage/payment of the study drug bevacizumab

- Refractory to standard therapy OR no standard therapy exists

- No advanced ovarian cancer or peritoneal carcinomatosis

- No metastases from any cancer causing significant ascites

- No lung malignancy with any of the following characteristics:

- In close proximity to a major vessel

- Centrally located

- Cavitary

- Squamous histology

- Hemoptysis > ½ teaspoon per day

PATIENT CHARACTERISTICS:

- ECOG performance status 0-1

- Platelet count ≥ 100,000/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- Bilirubin < 2 mg/dL

- AST or ALT < 3 times upper limit of normal

- Creatinine < 2 mg/dL

- Urine protein:creatinine ratio ≤ 1.0

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to tolerate oral therapy

- No bleeding diatheses or coagulopathy

- No impairment of gastrointestinal (GI) function or GI disease that may affect or
alter absorption of imatinib mesylate and/or cyclophosphamide (e.g., malabsorption
syndrome, history of total gastrectomy/significant small bowel resection)

- No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6
months

- No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg)

- No uncontrolled cardiovascular disease, including any of the following:

- Coronary artery disease

- Uncontrolled cardiac arrhythmia

- Symptomatic congestive heart failure (i.e., New York Heart Association class
II-IV)

- Unstable angina pectoris

- Clinically significant peripheral vascular disease

- No arterial thromboses within the past year, including any of the following:

- Transient ischemic attack

- Myocardial infarction

- Cerebrovascular event

- Unstable angina

- Angina requiring medical or surgical intervention

- Clinically significant peripheral artery disease

- Any other arterial thromboembolic event

- No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
lung

- No serious nonhealing wound, ulcer, or bone fracture

- No other active second malignancy except nonmelanoma skin cancer or cervical
carcinoma in situ unless therapy has been completed and < 30% risk for relapse exists

- No active infection or known HIV infection

- No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or
biologic composition to cyclophosphamide (i.e., alkylating agents)

- No history of noncompliance with medical regimens

- No known intolerance or hypersensitivity reaction to bevacizumab, imatinib mesylate,
or cyclophosphamide

- No other significant medical illness, psychiatric illness, or social situation that,
in the opinion of the investigator, would limit compliance with study requirements

- No inability to grant reliable informed consent

PRIOR CONCURRENT THERAPY:

- No major surgical procedure within the past 28 days or anticipated major surgery
during study treatment except for placement of a venous access device or surgery for
a diagnostic study